Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 38

Results For "infection"

525 News Found

USFDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences
Drug Approval | February 10, 2022

USFDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences

Adds five years of market exclusivity on approval


Gamida Cell initiates rolling submission of Biologics License Application for Omidubicel
Biotech | February 10, 2022

Gamida Cell initiates rolling submission of Biologics License Application for Omidubicel

On track to complete the BLA submission in the first half of 2022


Glenmark launches nasal spray to treat Covid-19
News | February 09, 2022

Glenmark launches nasal spray to treat Covid-19

Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process


Lay Sciences launch ImmynlgY, an oral antibody to neutralize Covid-19
Biotech | February 07, 2022

Lay Sciences launch ImmynlgY, an oral antibody to neutralize Covid-19

ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage that can potentially prevent viral entry, regardless of vaccination or infection status


Universal vaccination for Covid-19 irrational: AIIMS Professor
News | February 03, 2022

Universal vaccination for Covid-19 irrational: AIIMS Professor

The need is to vaccinate people who have not contracted Covid-19


Moderna’s Covid-19 `Spikevax’ vaccine gets full USFDA approval
Biotech | February 01, 2022

Moderna’s Covid-19 `Spikevax’ vaccine gets full USFDA approval

Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel


Alembic receives USFDA approval for clarithromycin tablets
Drug Approval | February 01, 2022

Alembic receives USFDA approval for clarithromycin tablets

Clarithromycin tablets USP, 250 mg and 500 mg have an estimated market size of US $ 11 million for twelve months ending September 2021 according to IQVIA


Lupin signs promotional agreement with Exeltis on SOLOSEC
News | January 28, 2022

Lupin signs promotional agreement with Exeltis on SOLOSEC

SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment


SQI Diagnostics inks pact with UK-Based Owlstone Medical
Biotech | January 25, 2022

SQI Diagnostics inks pact with UK-Based Owlstone Medical

Companies plan to commercialize breath-based detection of lung infection and transplant rejection


Pfizer and BioNTech evaluate Omicron specific Covid-19 vaccine
News | January 25, 2022

Pfizer and BioNTech evaluate Omicron specific Covid-19 vaccine

First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose